High-dose budesonide for early COVID-19.

Lipworth, Brian; Chan, Rory; Misirovs, Rasads

Lipworth, Brian; Chan, Rory; Misirovs, Rasads.

Lipworth B; Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK. Electronic address: b.j.lipworth@dundee.ac.uk.
Chan R; Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK.
Misirovs R; Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK.

Lancet ; 398(10317): 2147, 2021 12 11.

Article in English | MEDLINE | ID: covidwho-1560761

Subject(s)

Budesonide; COVID-19; Administration, Inhalation; Bronchodilator Agents/therapeutic use; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Budesonide / COVID-19 Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google